Basiliximab Intravenous and Eliglustat Tartrate

• Generic Name: basiliximab
• Dosage Forms: n.a.
• Other Brand Names: Simulect

Basiliximab belongs to a group of medicines known as immunosuppressive agents. It is used to lower the body's natural immunity in patients who receive kidney transplants.

When a patient receives a kidney transplant, the body's white blood cells will try to get rid of (reject) the transplanted kidney. Basiliximab works by preventing the white blood cells from getting rid of the transplanted kidney. The effect of basiliximab on the white blood cells may also reduce the body's ability to fight infections.

Basiliximab is to be administered only by or under the immediate supervision of your doctor.

• Generic Name: eliglustat
• Dosage Forms: n.a.
• Other Brand Names: Cerdelga

Long-term treatment of nonneuronopathic (type 1) Gaucher disease in patients who are extensive, intermediate, or poor metabolizers of CYP2D6.

Patient selection and dosing based on CYP2D6 metabolizer status; determine patient's CYP2D6 genotype with an FDA-cleared test prior to initiating therapy.

Ultrarapid CYP2D6 metabolizers may not achieve adequate plasma concentrations to achieve a therapeutic effect. A specific dosage cannot be recommended for patients whose CYP2D6 genotype cannot be determined (indeterminate metabolizers).

Designated an orphan drug by FDA for treatment of type 1 Gaucher disease.